Abstract
Over the past decade, we have witnessed significant advances in knowledge of the biology and treatment of chronic myeloid leukaemia (CML). The development of molecular-targeted therapy with tyrosine kinase inhibitors (TKIs) has fundamentally changed the outcome of this disease. Treatment with TKIs is now the standard of care in patients with CML and has dramatically improved long-term survival in the majority of patients. Patients who achieve major molecular response (MMR) after 2 years of treatment with imatinib have survival rates comparable to those of the general population. The success of TKIs has led to durable molecular response and possibility of normal life expectancies, such that it is now timely to address quality of life aspects such as fertility, pregnancy and family planning. Pregnancy in CML presents specific management and therapeutic challenges for the patient and the physician. Despite the recent treatment advances, we still have limited data on the safety of TKIs in pregnancy and its effect on fertility. However, there is a cause for concern and heightened awareness following the occurrence of a constellation of rare congenital malformations and spontaneous abortions in association with imatinib therapy. When a patient becomes pregnant whilst receiving TKI therapy, the difficulty lies in balancing the risk to the foetus of continuing therapy versus the risk to the patient of treatment interruption and potentially losing optimal disease response. All couples should be counselled on the risks associated with pregnancy whilst receiving TKI therapy. This is an essential aspect in patient care and frequently not emphasized enough by physicians. At the time of diagnosis, fertility preservation should be discussed with both male and female patients of childbearing potential. They should be made aware of fertility options which are available such as semen cryopreservation, ovarian or oocyte retrieval and storage and embryo cryopreservation in view of the potential detrimental effect of TKIs on fertility and gonadal function. The recommendation given to patients planning pregnancy differs according to their disease response to TKI therapy, which is the most important prognostic factor in CML.
Similar content being viewed by others
References
Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P (2010) Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029–1035
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122(4):515–522
(2014) Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation
(2014) Sprycel (dasatinib): prescribing information. Princeton, NJ: Bristol-Myers Squibb Company
(2014) Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation
He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ (2008) Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metabol Dispos 26(12):2564–2570
(2013) Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc
(2014) Inclusig (ponatinib) [prescribing information]. Cambridge, MA: Ariad Pharmaceuticals, Inc
Ault P, Kantarjian H, O’Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J (2006) Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24:1204–1208
Hensley ML, Ford JM (2003) Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40(2suppl3):21–25
Breccia M, Cannella L, Montefusco E, Frustaci A, Pacilli M, Alimena G (2008) Male patients with chronic myeloid leukemia treated with Imatinib involved in healthy pregnancies: report of five cases. Leuk Res 32(3):519–520
Ramasamy K, Hayden J, Lim Z, Mufti GJ, Ho AY (2007) Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 137(4):374–375
Iqbal J, Ali Z, Khan AU, Aziz Z (2014) Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma
Zhou L, You JH, Wu W, Li JM, Shen ZX, Wang AH (2013) Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res 37(10):1216–1221
Cortes J, O’Brien S, Ault P, Borthakur G, Jabbour E, Bradley-Garelik B, Debreczeni K, Yang D, Liu D, Kantarjian H (2008) Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood 112(11). Abstract 3230: Poster presented at: the 50th American Society of Hematology (ASH) Annual Meeting; December 6–9, 2008; San Francisco, USA
Gentile M, Guido M, Lucia E, Vigna E, Mazzone C, Recchia AG, Morabito F (2014) Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib. Leuk Lymphoma 55(3):709–710
Oweini H, Otrock ZK, Mahfouz RA, Bazarbachi A (2011) Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 283(1):133–134
Abrusezze E, Trawinska MM, Perrotti AP, De Fabritiis P (2014) Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 6(1):e2014028
Pye SM, Cortes J, Ault P, Hatfied A, Kantarjian H, Pilot R, Rosti G, Apperly J (2008) The effects of Imatinib on pregnancy outcome. Blood 111:5505–5508
Laferla JJ (1986) Spontaneous abortion. Clin Obstet Gynaecol 13:105–114
Soriano P (1997) The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 124:2691–2700
Bleyl SB, Moshrefi A, Shaw GM, Saijoh Y, Schoenwolf GC, Pennacchio LA, Slavotinek AM (2007) Candidate genes for congenital diaphragmatic hernia from animal models: sequencing of FOG2 and PDGFR alpha reveals rare variants in diaphragmatic hernia patients. Eur J Hum Genet 15:950–958
Sun T, Jayatilake D, Afink GB, Ataliotis P, Nistér M, Richardson WD, Smith HK (2000) A human YAC transgene rescues craniofacial and neural tube development in PDGFR alpha knockout mice and uncovers a role for PDGFR alpha in prenatal lung growth. Development 127:4519–4529
Bayraktar S, Morency B, Escalon MP (2010) Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester. BMJ Case Reports Online Publication
Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L, Ferreira PB, Dorliac-Lacer PE, Bendit I (2010) Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010:136252
Kroll T, Ames MB, Pruett JA, Fenske TS (2010) Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma 51(9):1751–1753
Dine G, Levert M, Rehn Y, Ali AN, Brahimi S, Gaillard B, Bocq I, Fumagalli G (2013) Two successful successive pregnancies in a woman with CML treated with dasatinib and temporary peg-interferon. J US-China Med Sci 10(5–6):128–133
Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide AL, Sauvageon H, Chapuis N, Tsatsaris V (2012) A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs 23(7):754–757
Conchon M, Sanabani SS, Bendit I (2009) Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 42(2)
Etienne G, Milpied B, Réa D, Rigal-Huguet F, Tulliez M, Nicolini FE (2010) French Intergroup of CML (Fi-LMC group). Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group). Bull Cancer 97(8):997–1009
Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE, Lee J, Kim D, Kim WS, Park SH, Kweon IY (2009) Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukaemia: implications for intermittent imatinib therapy. Leuk Lymphoma 50(6):944–951
Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J, Bua M, Reid A, Foroni L, Rezvani K, Goldman J, Marin D (2010) Poor outcome after reintroduction of imatinib in patients with CML who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116(6):1014–1016
Baer MR, Ozer H, Foon KA (1992) Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol 81(2):167–169
Mubarak AA, Kakil IR, Awidi A, Al-Homsi U, Fawzi Z, Kelta M, Al-Hassan A (2002) Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-a in 1st trimester: report of 3 cases and review of the literature. Am J Hematol 69:115–118
Hiratsuka M, Minakami H, Koshizuka S, Sato I (2000) Administration of interferon-a during pregnancy: effect on fetus. J Perinat Med 28:372–376
Vantroyen B, Vanstraelen D (2002) Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha 2a and no treatment. A comprehensive analysis of the literature. Acta Hematol 107:158–169
Regierer AC, Schulz CO, Kuehnhardt D, Flath B, Possinger K (2006) Interferon a—therapy for chronic myeloid leukemia during pregnancy. Am J Hematol 81:149–156
Al Bahar S, Pandita R, Nath SV (2004) Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. Int J Gynecol Obstet 85:281–282
Kuroiwa M, Gondo H, Ashida K, Kamimura T, Miyamoto T, Niho Y, Tsukimori K, Nakano H, Ohga S (1998) Interferon alpha therapy for chronic myeloid leukemia during pregnancy. Am J Hematol 59:101–102
Thauvin Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, Casasnovas RO, Douvier S, Nivelon-Chevallier A (2001) Exposure to hydroxyurea during pregnancy: a case series. Leukemia 15:1309–1311
Fadilah SA, Ahmad-Zailani H, Soon-Keng C, Norlaila M (2002) Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 16:1202–1203
Russel MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ (2007) Imatinib mesylate and metabolite concentration in maternal blood, umbelical cord blood, placenta and breast milk. J Perinatol 27:241–243
Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, Yorulmaz H, Tunali A (2009) Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 280(2):169–175, 2008
(2006) Bristol-Myers Squibb Canada. HYDREA® product monograph. Montreal, Quebec
Kumar AR, Hale TW, Mock RE (2000) Transfer of interferon alfa into human breast milk. J Hum Lact 16(3):226–228
Lichtman MLJ (2001) 6th ed. Vol. 1047. New York, NY: McGraw-Hill. Acute myelogenous leukemia. Williams Hematology
Sheehy WT (1958) An evaluation of the effect of pregnancy on chronic granulocytic leukaemia. Am J Obstet Gynecol 75:788
Ali R, Ozkalemkaş F, Ozkocaman V, Ozçelik T, Ozan U, Kimya Y, Tunali A (2004) Successful pregnancy and delivery in patient with CML and management of CML with leukapheresis during pregnancy. Jpn J Clin Oncol 34:215–217
Klaasen R, de-Jong P, Wijermans PW (2007) Successful management of chronic myeloid leukemia with leucapheresis during a twin pregnancy. Neth J Med 65:147–149
Acknowledgments
RP, DM and JFA are grateful to the National Institute of Health Research (NIHR) and the NIHR Biomedical Research Centre for the financial support.
Author contributions
RP, DM and JFA performed the literature review and wrote the manuscript.
Conflict of interest
Authors declare no conflict of interest with regard to this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Palani, R., Milojkovic, D. & Apperley, J.F. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 94 (Suppl 2), 167–176 (2015). https://doi.org/10.1007/s00277-015-2317-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-015-2317-z